tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Fibroadenoma D018226 2 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Glucose Intolerance D018149 13 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Hypophosphatemia D017674 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Mucinoses D017520 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Porokeratosis D017499 1 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Hyperpigmentation D017495 11 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Polymyositis D017285 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgG Deficiency D017099 1 associated lipids
IgA Deficiency D017098 2 associated lipids
Liver Failure D017093 5 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Critical Illness D016638 13 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Fungemia D016469 2 associated lipids
Sweet Syndrome D016463 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Vestibular Diseases D015837 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis D015614 2 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Scleritis D015423 3 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Discitis D015299 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Dementia, Vascular D015140 7 associated lipids
Wounds, Stab D014951 3 associated lipids
West Nile Fever D014901 1 associated lipids
Vomiting D014839 21 associated lipids
Vitiligo D014820 2 associated lipids
Vision Disorders D014786 10 associated lipids
Viremia D014766 4 associated lipids
Venous Insufficiency D014689 2 associated lipids
Vasculitis D014657 14 associated lipids
Vascular Diseases D014652 16 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Oberholzer J et al. Daclizumab as escape therapy for late acute kidney rejection in the presence of FK506 nephrotoxicity. 2000 Transpl. Int. pmid:10836657
Yoshikawa T et al. In vivo osteogenic capability of cultured allogeneic bone in porous hydroxyapatite: immunosuppressive and osteogenic potential of FK506 in vivo. 2000 J. Bone Miner. Res. pmid:10841184
Rabinowitz M et al. Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands. 2000 Bioorg. Med. Chem. Lett. pmid:10843203
Nasr IS Topical tacrolimus in dermatology. 2000 Clin. Exp. Dermatol. pmid:10844509
Samsonov D et al. Enhancement of immune tolerance via induction of NK1.1 positive liver-associated-lymphocytes under immunosuppressive conditions. 2000 J. Hepatol. pmid:10845669
Zhang F et al. Resistance to Friend murine leukemia virus infection conferred by the Fv-4 gene is recessive but appears dominant from the effect of the immune system. 2000 J. Virol. pmid:10846105
Small bowel transplants in adults and multivisceral transplants in adults and children. 1999 Tecnologica MAP Suppl pmid:10848042
Tyedmers J et al. Assembly of heterodimeric luciferase after de novo synthesis of subunits in rabbit reticulocyte lysate involves hsc70 and hsp40 at a post-translational stage. 2000 Eur. J. Biochem. pmid:10848974
Gibson SW et al. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. 2000 Transplantation pmid:10852592
Konrad T et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. 2000 Transplantation pmid:10852599
Schvarcz R et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). 2000 Transplantation pmid:10852623
Rollins CT et al. A ligand-reversible dimerization system for controlling protein-protein interactions. 2000 Proc. Natl. Acad. Sci. U.S.A. pmid:10852943
Florio G et al. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. 2000 AIDS pmid:10853974
Kochi S et al. Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. 2000 Life Sci. pmid:10855946
Bultynck G et al. Effects of the immunosuppressant FK506 on intracellular Ca2+ release and Ca2+ accumulation mechanisms. 2000 J. Physiol. (Lond.) pmid:10856121
Granot E et al. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation. 2000 Transplant. Proc. pmid:10856551
Ben-Ari Z et al. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy. 2000 Transplant. Proc. pmid:10856553
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Morelli AE et al. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus. 2000 J. Immunol. pmid:10861056
Boubenider S et al. Interaction between theophylline and tacrolimus in a renal transplant patient. 2000 Nephrol. Dial. Transplant. pmid:10862651
Wu K et al. The FK520 gene cluster of Streptomyces hygroscopicus var. ascomyceticus (ATCC 14891) contains genes for biosynthesis of unusual polyketide extender units. 2000 Gene pmid:10863099
Oike F et al. A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. 2000 Transplantation pmid:10868630
Yamani MH et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. 2000 Transplantation pmid:10868634
Blakolmer K et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. 2000 Transplantation pmid:10868635
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Au WY et al. Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin. 2000 Haematologica pmid:10870125
Queille-Roussel C et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. 2000 Contact Derm. pmid:10871099
Morales JM et al. Immunosuppression in older renal transplant patients. 2000 Drugs Aging pmid:10874523
Costantini LC and Isacson O Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. 2000 Exp. Neurol. pmid:10877916
Castilho RF et al. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. 2000 Exp. Neurol. pmid:10877919
Allison AC Immunosuppressive drugs: the first 50 years and a glance forward. 2000 Immunopharmacology pmid:10878284
Assmann T et al. Applications of tacrolimus for the treatment of skin disorders. 2000 Immunopharmacology pmid:10878290
Hamazaki T et al. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors]. 2000 Rinsho Ketsueki pmid:10879106
Ben Abraham R et al. [FK506 (tacrolimus) does not increase hepatic damage due to hypoperfusion]. 2000 Harefuah pmid:10883243
Romano G et al. Systemic and intratubular effects of cyclosporin-A and tacrolimus on the rat kidney. 2000 Eur. J. Pharmacol. pmid:10884522
Parker EM et al. Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. 2000 Neuropharmacology pmid:10884572
Terashima A et al. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons. 2000 Neuropharmacology pmid:10884573
Zaman AK Effects of tacrolimus hydrate (FK-506) on the expression of tissue factor in THP-1 human monocyte cell line. 2000 Hokkaido Igaku Zasshi pmid:10884973
Arthur JM and Shamim S Interaction of cyclosporine and FK506 with diuretics in transplant patients. 2000 Kidney Int. pmid:10886578
Hooijberg E et al. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. 2000 Blood pmid:10887106
Mori A et al. Control of IL-5 production by human helper T cells as a treatment for eosinophilic inflammation: comparison of in vitro and in vivo effects between selective and nonselective cytokine synthesis inhibitors. 2000 J. Allergy Clin. Immunol. pmid:10887335
Yue G et al. The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells. 2000 Am. J. Physiol., Cell Physiol. pmid:10898719
Mukerjee N et al. Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. 2000 Arch. Biochem. Biophys. pmid:10898953
Hishinuma S and Ogura K Ca(2+)/calmodulin-mediated regulation of the desensitizing process in G(q) protein-coupled histamine H(1) receptor-mediated Ca(2+) responses in human U373 MG astrocytoma cells. 2000 J. Neurochem. pmid:10899954
Wang L et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. 2000 Clin. Exp. Pharmacol. Physiol. pmid:10901387
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262